The L1210 assay for immune complexes: Application in cancer patients and correlation with disease progress

✍ Scribed by Paula K. F. Poskitt; Thomas R. Poskitt

• Publisher: John Wiley and Sons
• Year: 1979
• Tongue: French
• Weight: 544 KB
• Volume: 24
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910240507

✦ Synopsis

Abstract

Immune complexes (ICs) were determined by the non‐complement‐dependent L1210 radioimmune assay on 132 serum samples collected from 53 patients with a variety of cancers. Both the mean IC levels and frequency of positive tests were significantly greater in cancer patients (mean = 96±100 μg/ml, 46% positive) than in a control group of 67 normal healthy blood donors (mean = 39±15, 3% positive). When cancer patients were assorted into groups by disease progress, those with large or progressing tumors had significantly higher mean values (136±129) and frequency of positives (75%) than those with small or regressing tumors (58±18, 22% positive). In lung cancer patients, IC levels showed a strong inverse correlation (r~s~ = −0.903) with survival time in patients who died, and appeared to be a better prognostic indicator than performance status (Karnofsky scale) at time of diagnosis. Serial IC measurements taken on several patients showed a decrease in levels concomitant with a favorable response to cytoreductive therapy, sustained normal levels during periods of prolonged remission, and a rise to elevated levels with (and sometimes preceding) documentation of new metastases.